HIV/AIDS Update - New new FDA Guidance for Industry: Developing Antiretroviral Drugs for Treatment

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: HIV/AIDS Update - New new FDA Guidance for Industry: Developing Antiretroviral Drugs for Treatment

You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

The Food and Drug Administration recently published new Guidance for Industry Human Immunodeficiency Virus-1 Infection:  Developing Antiretroviral Drugs for Treatment

The new guidance provides recommendations for the development of antiretroviral drugs regulated within the FDA's Center for Drug Evaluation and Research (CDER) for the treatment of human immunodeficiency virus-1 (HIV-1 or HIV) infection. Specifically, this guidance addresses the overall development program and clinical trial designs for antiretroviral drugs to support an indication for the treatment of HIV-1 infection.

This guidance revises the October 2002 guidance for industry Antiretroviral Drugs Using Plasma HIV-RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval.

The Guidance includes general considerations, including those related to pharmacology/toxicology

Significant changes from the 2002 version include:

1. more details on nonclinical development of antiretroviral drugs
2. a greater emphasis on recommended trial designs for HIV-1-infected heavily treatment-experienced patients (those with multiple-drug resistant virus and few remaining therapeutic options)
3. use of a primary endpoint evaluating early virologic changes for studies in heavily treatment-experienced patients; and
4. use of the traditional approval pathway for initial approval of new antiretrovirals with primary analysis time points dependent on the indication sought.

This guidance does not address the use of antiviral drugs for preventing the transmission of HIV-1 infection, development of therapeutics (without antiviral mechanisms) intended to mitigate or reverse clinical or pathophysiological outcomes of immunologic suppression of HIV-1 infection, and general issues of clinical trial design or statistical analyses for HIV antiretroviral trials.

Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration

Kimberly Struble
Division of Antiviral Products
Food and Drug Administration

Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration

 

If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDA Patient Network News, a twice monthly newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients and patient advocates.  And please visit FDA's new patient-focused web site, PatientNetwork.fda.gov.

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420